(English) New Publication in Nature Cancer Demonstrates Signatera’s Ability to Evaluate Tumor Response to Immunotherapy

SAN CARLOS, Calif., Aug. 3, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a manuscript in Nature Cancer¹ that validates the ability of its Signatera™ personalized circulating tumor DNA (ctDNA) technology to evaluate…